GGHC
ALDR

Gilder Gagnon Howe & Co’s Alder Biopharmaceuticals ALDR Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-3,193
Closed -$80K – 294
2016
Q2 		$80K Buy
+3,193
New +$86.4K ﹤0.01% 252

Other funds holding ALDR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Gilder Gagnon Howe & Co's ALDR Position: Q3 2016 in Review

Gilder Gagnon Howe & Co sold out of Alder Biopharmaceuticals (ALDR) in Q3 2016, closing a stake of 3,193 shares — an estimated $80K sold.

Gilder Gagnon Howe & Co first reported a position in ALDR in Q2 2016 and held it in 1 quarter. The position peaked at $80K in Q2 2016. 159 funds tracked by Wall St. Rank hold ALDR as of Q3 2016.

  • Gilder Gagnon Howe & Co reported no remaining Alder Biopharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 3,193 Alder Biopharmaceuticals shares in Q3 2016, an estimated $80K.
  • Gilder Gagnon Howe & Co first reported a position in Alder Biopharmaceuticals in Q2 2016 and held it in 1 quarter.
  • Gilder Gagnon Howe & Co's Alder Biopharmaceuticals position peaked at $80K in Q2 2016.
  • 159 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q3 2016.

Based on Gilder Gagnon Howe & Co's 13F filing for Q3 2016, filed 1 Nov 2016.